Pomalidomide 3mg capsules
NHS hospitals in England used £17,072,818 of indicative cost of Pomalidomide 3mg capsules in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 31.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Pomalidomide 3mg capsules: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Pomalidomide 3mg capsules most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £1,238,771 |
| University Hpls Of Leicester Nhs Trust | £671,691 |
| The Royal Marsden Nhs Foundation Trust | £634,486 |
| South Tyneside And Sunderland Nhs Ft | £576,410 |
| Univ Hpl B/Ham Nhs Foundation Trust | £520,994 |
| Western Sussex Hospitals Nhs Found Trust | £515,837 |
| Shrewsbury & Telford Hospital Nhs Trust | £425,311 |
| The Christie Nhs Foundation Trust | £409,610 |
| Hampshire Hospitals Nhs Foundation Trust | £408,866 |
| Sheffield Teaching Hospitals Nhs Trust | £400,598 |
The primary-care picture
Pomalidomide is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Pomalidomide medicine page.